



## Early Biological Reactions on Biomaterials Determining Long-Term Tissue Regeneration Effects

Guest Editors:

**Prof. Dr. Bilal Al-Nawas**

Klinikum der Johannes-  
Gutenberg-Universität und  
Fachbereich Medizin, Mainz,  
Germany

**Dr. Peer Wolfgang Kämmerer**

Department of Oral and  
Maxillofacial Surgery, University  
Medical Centre Mainz, 55131  
Mainz, Germany

Deadline for manuscript  
submissions:

**closed (15 February 2022)**

### Message from the Guest Editors

Dear Colleagues,

After implantation of a biomaterial, a plethora of biological host reactions such as platelet-derived cytokine release, inflammatory or general early wound healing responses including adhesion of relevant cells and (neo-) angiogenesis take place, affecting local homeostasis. Some of these interactions have been topics of clinical and scientific discussion (e.g., the role of membranes in bone regeneration), while others are well understood (e.g., physical surface modification of implants). The goal is to specifically tailor tissue-implant interactions in order to achieve an improved and stable long-term tissue integration and regeneration. The focus of this Special Issue is interdisciplinary research on bioactive modifications of known and newly established (including 3D-printed) biomaterials with factors which are relevant for early tissue homeostasis, as well as the creation of a local wound environment that is optimal for the respective healing. In brief, methods are needed that allow the realistic and cost-efficient production of functionally improved biomaterials, contributing to patient care at a high level in the future.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI